REFERENCES

1. United Nations. The Millennium Development Goals Report: 2015. New York: United Nations; 2015. Available at: http://www.un.org/ milleniumgoals/2015_MDG_Report.

2. United Nations.

3. Darroch JE, Singh S. Trends in contraceptive need and use in de­veloping countries in 2005, 2008, 2012: an analysis of national sur­veys. Lancet 2013;381:1756-62.

4. Boden JM, Fergusson DM, Horwood LJ. Early motherhood and subsequent life outcomes. J Child Psychol Psychiatry 2008;49: 151-60.

5. Sedgh G, Singh S, Hussain R. Intended and unintended preg­nancies worldwide in 2012 and recent trends. Stud Fam Plann 2014;45:301-14.

6. Vollmer LR, van der Spuy ZM. Contraceptive usage and timing of pregnancy among pregnant teenagers in Cape Town, South Africa. Int J Gynecol Obstet 2016;133:334-37.

7. World Health Organization (WHO). Ensuring Human Rights in the Provision of Contraceptive Information and Services: Guidance and Recommendations. Geneva: WHO; 2014. Available at: http:// apps.who.int/iris/bitstream/10665/102539/1/9789241506748_ eng.pdf (accessed 10 September 2015).

8. Cottingham J, Germain A, Hunt P. Use of human rights to meet the unmet need for family planning. Lancet 2012;380:172-80.

9. Trussell J. Contraceptive efficacy. In: Hatcher RA, Trussell J, Nelson AL, Cates W, Dowal D, Policar M (eds), Contraceptive Technology, 20th rev edn, pp. 779-844. New York, NY: Argent Media; 2011.

10. World Health Organization. Medical eligibility criteria for contraceptive use, executive summary, 5th edn. 2015. Available at: http://apps.who.int/iris/bitstream/10665/172915/1/WHO_ RHR_15.07_eng.pdf?ua=1&ua=1 (accessed 10 September 2015).

11. World Health Organization (WHO). Medical Eligibility Criteria

for Contraceptive Use: A WHO Family Planning Cornerstone, 5th edn.

cessed 26 May 2016).

12. Meuck AO, Seeger H. Pharmacology of dienogest. Gynaecol Forum 2009;14:2.

13. Sitruk-Ware R. Pharmacological profile of progestins. Maturitas 2008;61:151-57.

14. Sitruk-Ware R. New progestagens for contraceptive use. Hum Reprod Update 2006;12:169-78.

15. Sitruk-Ware R, Nath A. The use of newer progestins for contra­ception. Contraception 2010;82:410-17.

16. Coney P, Washenik K, Langley RG, et al. Weight change and adverse event incidence with a low-dose oral contraceptive: two random­ized, placebo-controlled trials. Contraception 2001;63:297-302.

17. Westhoff C, Morroni C, Kerns J, et al. Bleeding patterns after im­mediate vs. conventional oral contraceptive initiation: a random­ized, controlled trial. Fertil Steril 2003;79:322-29.

18. Gallo M, Lopez L, Grimes D, et al. Combination contraceptives: ef­fects on weight. Cochrane Database Syst Rev 2014;1:CD003987.

19. Dragoman, Monica V The combined oral contraceptive pill- re­cent developments, risks and benefits. Best Prac Res Clini Obstet Gynaecol 2014;28:825-34.

20. Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists (FSRH). UK Medical Eligibility Criteria for Contraceptive Use (UKMEC 2016). London: FSRH; 2016. Available at: https://www.fsrh.org/docu- ments/ukmec-2016/ (accessed 25 May 2016).

21. National Department of Health, Republic of South Africa. National contraception clinical guidelines. 2012. Available at: https://www.gov.za/sites/default/files/gcis_document/201409/ contraceptionclinicalguidelines28jan2013-2.pdf.

22. Van Vliet HA, Grimes DA, Helmerhorst FM, et al. Biphasic versus triphasic oral contraceptives for contraception. Cochrane Database Syst Rev 2006;3:CD003283.

23. Van Vliet HA, Grimes DA, Lopez LM, et al. Triphasic versus monophasic oral contraceptives for contraception.

24. World Health Organization (WHO). Comparing Typical Effectiveness of Contraceptive Methods. Geneva: WHO; 2006. Available at: http://www.ffii.org/nr/shared/enFHI/Resources/ EffectivenessChart.pdf.

25. Li HWR, Lo SST, Ho PC. Emergency contraception. Best Prac Res Clin Obstet Gynaecol 2014;28:835-44.

26. Yuzpe AA, Thurlow HJ, Ramzy I, et al. Post coital contraception: a pilot study. J Reprod Med 1974;13:53-59.

27. Task Force on Postovulatory Methods of Fertility Regulation. Randomised controlled trial of levonorgestrel versus the Yuzpe regimen of combined oral contraceptives for emergency contra­ception. Lancet 1998;352:428-33.

28. Cleland K, Zhu H, Goldstuck N, Cheng L, Trussell J. The efficacy of intrauterine devices for emergency contraception: a systematic re­view of 35 years of experience. Human Reprod 2012;37:1994-2000.

29. Hamoda H, Ashok PW, Stalder C, Flett GMN, Kennedy E, Templeton A. A randomized trial of mifepristone (10mg) and levonorgestrel for emergency contraception. Obstet Gynecol 2004;104:1307-15.

30. Glasier A, Thong KJ, Dewar M, et al. Mifepristone (RU 486) com­pared with high-dose estrogen and progestogen for emergency contraception: a randomized trial. N Engl J Med 1992;327:1041-44.

31. Moreau C, Trussell J. Results from pooled phase III studies of ulipristal acetate for emergency contraception. Contraception 2012;86:673-80.

32. Noe G, Croxatto HB, Salvatierra AM, et al. Contraceptive efficacy of emergency contraception with levonorgestrel given before and after ovulation. Contraception 2010;81:414-20.

33. Trussell J. Contraceptive failure in the United States. Contraception 2011;83:397-404.

34. Peterson HB, Darmstadt GL, Bongaarts J, et al. Meeting the unmet need for family planning: now is the time. Lancet 2013;381;1696-99.

35. Glasier AF, Anakwe R, Everington D, et al. Would women trust their partners to use a male pill? Hum Reprod 2000;15:646-49.

36. Martin CW, Anderson RA, Cheng L, et al.

37. Roth MY, Page ST, Bremner WJ. Male hormonal contracep­tion: looking back and moving forward. Andrology 2016;4:4-12.

38. Wang C, Festin MPR, Swerdloff RS. Male hormonal contracep­tion: where are we now? Curr Obstet Gynecol Rep 2016;5:38-47.

39. Chao J, Page ST, Anderson RA. Male contraception. Best Prac Res Clin Obstet Gynaecol 2014;28:845-57.

40. Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists (FSRH). Intrauterine Contraception. London: FSRH; 2015.

41. Kulier R, O’Brien P, Helmerhorst FM, Usher-Patel M, d’Arcangues C. Copper containing, framed intrauterine devices for contracep­tion. Cochrane Database Syst Rev 2007;7;CD005347.

42. Farley TMM, Rosenberg MJ, Rowe P, Chen JH, Meirik O. Intrauterine devices and inflammatory disease: an international perspective. Lancet 1992;339:785-88.

43. Grimes DA, Schulz KF. Antibiotic prophylaxis for intrauterine contraceptive device insertion. Cochrane Database of Syst Rev 1999;3:CD001327.

44. Pile JM, Barone MA. Demographics of vasectomy - USA and international. Urol Clin North Am 2009;36:295-305.

45. Hardman SMR, Gebbie AE. The contraceptive needs of the perimenopausal woman. Best Prac Res Clin Obstet Gynaecol 2014;28:903-15.

46. Peterson HB, Xia Z, Highes JM, Wilcox IS, Tylor LR, Trussell J. The risk of pregnancy after tubal sterilization: findings from the US Collaborative Review of Sterilization. Am J Obstet Gynecol 1996;174:1611-70.

47. Black A, Guilbert E. Canadian Contraception Consensus (Part 2 of 4) [SOGC Clinical Practice Guideline No 329. November 2015]. J Obstet Gynaecol Can 2015;37:S1-39.

48. Kovacs GT, Krins AJ. Female sterilizations with Filshie clips: what is the risk of failure? A retrospective survey of 30 000 applications. JFam Plann Reprod Health Care 2002;28:34-35.

49. Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists (FSRH). Male and fe­male sterilisation summary of recommendations. 2014. Available at: http://www.fsrh.org/pdfs/MaleFemaleSterilisationSummary. pdf (accessed April 2016).

50. Moss C, Isley MM. Sterilization. A review and update. Obstet Gynecol Clin N Am 2015;42:713-24.

51. Beksinska M, Smit J, Mabude Z, Vijayakumar G, Joanis C. Performance of the Reality polyurethane female condom and a synthetic latex prototype: a randomized crossover trial among South African women. Contraception 2006;73:386-93.

52. Van Damme L, Ramjee G, Alary M, et al. Effectiveness ofCOL- 1492, a nonoxynol-9 vaginal gel, on HIV-1 transmission in female sex workers: a randomised controlled trial. Lancet 2002;360:971-77.

53. Obiero J, Murethera PG, Hussey GD, Wiysonge CS. Vaginal microbicides for reducing the risk of sexual acquisition of HIV infection in women: systematic review and meta-analysis. BMC InfectDis 2012;12:289.

54. Raymond EG, Trussell J, Weaver MA, Reeves MF. Estimating contraceptive efficacy: the case of spermicides. Contraception 2013;87:134-37.

55. Freundl G, Sivin I, Batar I. State-of-the-art of non-hormonal methods of contraception. Eur J Contracept Reprod Health Care 2010;15:113-23.

56. Arevalo M, Jennings V, Sinai I. Efficacy of a new method of family planning: the standard days method. Contraception 2002;65:333-38.

57. Oosterhoff P, Dkhar B, Albert S. Understanding unmet contracep­tive needs among rural Khasi men and women in Meghalaya. Cult Health Sex 2015;17:1105-18.

58. Grimes DA, Gallo MF, Halpern V, Nanda K, Schulz KF, Lopez LM. Fertility awareness-based methods for contraception. Cochrane Database Syst Rev 2004;4:CD004860.

59. Winner B, Peipert JF, Qiuhong Z, et al. Effectiveness oflong- acting reversible contraception. N Eng J Med 2012;366:1998-2007.

60. Kluge J, Steyn PS. Long acting reversible contraception. Obstet Gynaecol Forum 2010;20:21-27.

61. Conde-Agudelo A, Rosas-Bermudez A, Kafury-Goeta AC. Birth spacing and risk of adverse perinatal outcomes: a meta-analysis. JAMA 2006;295:1809-23.

62. Conde-Agudelo A, Rosas-Bermudez A, Kafury-Goeta AC. Effects of birth spacing on maternal health: a systematic review. Am J Obstet Gynecol 2007;196:297-308.

63. Steyn PS, Goldstuck NM. Postpartum contraception. Obstet Gynaecol Forum 2013;23:9-13.

64. National Institute for Health and Care Excellence (NICE). Postnatal Care up to 8 Weeks after Birth. Clinical guideline [CG37], last updated February 2015. London: NICE; 2006. Available at: https://www.nice.org.uk/guidance/cg37.

65. Royal College of Obstetricians and Gynaecologists (RCOG). Leading Safe Choices: Best Practice in Postpartum Family Planning. Best Practice Paper No. 1. London: RCOG; 2015.

66. Goldstuck ND, Steyn PS. Intrauterine contraception after ce­sarean section and during lactation: a systematic review. Int J Womens Health 2013;5:811-18.

67. Royal College of Obstetricians and Gynaecologists (RCOG). Leading Safe Choices: Best Practice in Comprehensive Abortion Care. Best Practice Paper No. 2. London: RCOG; 2015.

68. World health Organization. Hormonal contraceptive eligibility for women at high risk of HIV Guidance-Recommendations con­cerning the use of hormonal contraceptive methods by women at high risk of HIV (2017). https://www.who.int/reproductivehealth/ publications/family_planning/HC-and-HIV-2017/en/ (accessed 28 July 2019).

69. Polis CB, Curtis KM, Hannaford P, et al. Update on hormonal contra­ceptive methods and risk of HIV acquisition in women: a systematic review of epidemiological evidence. AIDS 2016;30(17):2665-83.

70. Steyn PS, Goldstuck ND. Contraceptive needs of the adolescent. Best Pract Res Clin Obstet Gynaecol 2014;28:891-901.

71. Dodson NA, Gray SN, Burke PJ. Teen pregnancy prevention on a LARC: an update on long- acting reversible contraception for the primary care provider. Curr Opin Paediatr 2012;24:439-45.

72. McNicholas C, Peipert JF. Long acting reversible contraception for adolescents. Curr Opin Obstet Gynecol 2012;24:293-98.

73. Lumsden MA, Gebbie A, Holland C. Managing unsched­uled bleeding in non-pregnant premenopausal women. BMJ 2013;346:f3251.

74. Gebbie AE, Glasier A, Sweeting V. Incidence of ovulation in peri- menopausal women before and during replacement therapy. Contraception 1995;52:221-22.

75. Beksinska ME, Smit JA, Kleinschmidt I, Farlay TMM. Assessing menopausal status in women aged 40-49 using depot- medroxyprogestrone acetate, norethisterone enantiate or com­bined oral contraception. S Afr Med J 2011;101:131-34.

76. Vessey M, Yeates D. Oral contraceptive use and cancer: final re­port from the Oxford-Family Planning Association Contraceptive Study. Contraception 2013;88:678-83.

77. Cibula P, Gompel A, Mueck AO, et al. Hormonal contraception and risk of cancer. Hum Reprod Update 2010;16:631-50.

78. Wilailak S, Vipupinyo C, Suraseramvong V, et al. Depot medroxyprogesterone acetate and epithelial ovarian cancer: a multicentre case-control study. BJOG 2012;119:672-77.

79. Blumel JE, Castelo-Branco C, Binfa L, Aparicio R, Mamami L. A scheme of combined oral contraceptives for women more than 40 years old. Menopause 2001;8:286-89.

80. Faculty of Sexual and Reproductive Healthcare of the Royal College of Obstetricians and Gynaecologists (FSRH). Contraception for women aged over 40 years. 2010. Available at: http://www.fsrh.org/pdfs/ContraceptionOver40July10.pdf (ac­cessed April 2016).

81. Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013;347: fS298.

82. Mansour D, Korver T, Marintcheva-Petrova, Fraser IS. 'The ef­fects of Implanon® on bleeding patterns. Eur J Contracept Reprod Health Care 2008;13 Suppl 1:13-28.

83. Espey E, Ogburn T, Fotieo D. Contraception: what every internist should know. Med Clin N Am 2008;92:1037-58.

84. Sliwa K, Anthony J. Late maternal deaths: a neglected responsi­bility. Lancet 2016;387f:2072-73.

85. Thorne S, Nelson-Piercy C, MacGregor A, et al. Pregnancy and contraception in heart disease and pulmonary arterial hyperten­sion. J Fam Plann Reprod Health Care 2006;32:75-81.

86. Folger SG, Curtis KM, Tepper NK, Gaffield ME, Marchbanks PA. Guidance on medical eligibility criteria for contraceptive use: iden­tification of research gaps. Contraception 2010;82:113-18.

87. Family Planning 2020. Accelerating access. Available at: http:// www.familyplanning2020.org/ (accessed 30 May 2016).